H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Fri, 16 Oct 2026 06:56:09 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $130.00 price target on Halozyme Therapeutics (NASDAQ: HALO).

The analyst commented: "Switching Takeda’s primary immunodeficiency patients from GAMMAGARD LIQUID or CUVITRU to TAK-881 could add Halozyme royalties. On October 14, Takeda (TAK; not rated) presented detailed Phase 2/3 IgGNITE results for its investigational 20% subcutaneous immunoglobulin (SCIG) with Halozyme’s recombinant human hyaluronidase (ENHANZE) in primary immunodeficiency (PID). Median single-site infusions took 75.8 vs. 132 minutes with HYQVIA, a 42.6% reduction; two-site infusions took 58.3 vs. 86 minutes, a 32.2% reduction. The same IgG dose required half the volume, with dosing

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date

Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Tue, 13 Oct 2026 16:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Russell Investments Canada Limited (“Russell Investments Canada”) today announced cash distributions for the ETF Series and ETFs for the months of October, and November. Unitholders of record of the ETF Series and ETFs, as of the Record Date, will receive a per-unit cash distribution payable on the Payment Date
Details of the per-unit cash distribution amount are as follows:

Fund Name

Ticker
Symbol

Cash Distribution
per Unit

Halozyme Therapeutics (HALO) PT Raised to $130 at TD Cowen

Tue, 13 Oct 2026 09:39:11 -0400
TD Cowen analyst Brendan Smith raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $130.00 (from $105.00) while maintaining a rating.

H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Tue, 13 Oct 2026 06:47:49 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $130.00 price target on Halozyme Therapeutics (NASDAQ: HALO).
The analyst commented: "FDA approval of Tecentriq Hybreza in Stage 3 dMMR colon cancer adds a 12-month adjuvant royalty opportunity for HALO. On October 8, the FDA announced approval of Roche's Tecentriq (atezolizumab) and ENHANZE-enabled Tecentriq Hybreza (atezolizumab and hyaluronidase) in combo with fluoropyrimidine and oxaliplatin chemo for patients with Stage 3 mismatch repair-deficient (dMMR) colon cancer (see FDA announcement). The decision establishes the first approved adjuvant immunotherapy regimen for this population, with Phase 3 ATOMIC (n=712) demonstrating 36-month disease-free survival (DFS) of

Form 4 HALOZYME THERAPEUTICS, For: Oct 06 Filed by: Torley Helen

Thu, 08 Oct 2026 19:56:00 -0400
si-local-file:///var/storage/secattach/20261008/27167998.html

Form 4/A HALOZYME THERAPEUTICS, For: May 05 Filed by: Connaughton Bernadette

Thu, 08 Oct 2026 19:55:00 -0400
si-local-file:///var/storage/secattach/20261008/27167997.html

Halozyme Therapeutics (HALO) PT Raised to $78 at JPMorgan

Thu, 08 Oct 2026 08:09:29 -0400
JPMorgan analyst Jessica Fye raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $78.00 (from $70.00) while maintaining a Neutral rating.

Halozyme stock rises after winning injunction against Merck

Wed, 07 Oct 2026 11:37:31 -0400

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets.

The specialized Dutch patent court in the Hague ruled that Merck infringed Halozyme's MDASE patent EP 2,797,622 and ordered MSD BV to halt manufacturing, offering, placing on the market, using, importing or stocking Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The court also rejected Merck's arguments that the EP622 patent is invalid.

"We're very pleased the Dutch court recognized the validity and infringement of Halozyme's MDASE patent EP622 and granted an

Halozyme stock rises after winning injunction against Merck

Wed, 07 Oct 2026 11:37:31 -0400

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets.

The specialized Dutch patent court in the Hague ruled that Merck infringed Halozyme's MDASE patent EP 2,797,622 and ordered MSD BV to halt manufacturing, offering, placing on the market, using, importing or stocking Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The court also rejected Merck's arguments that the EP622 patent is invalid.

"We're very pleased the Dutch court recognized the validity and infringement of Halozyme's MDASE patent EP622 and granted an

Halozyme stock rises after winning injunction against Merck

Wed, 07 Oct 2026 11:37:31 -0400

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets.

The specialized Dutch patent court in the Hague ruled that Merck infringed Halozyme's MDASE patent EP 2,797,622 and ordered MSD BV to halt manufacturing, offering, placing on the market, using, importing or stocking Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The court also rejected Merck's arguments that the EP622 patent is invalid.

"We're very pleased the Dutch court recognized the validity and infringement of Halozyme's MDASE patent EP622 and granted an

Halozyme stock rises after winning injunction against Merck

Wed, 07 Oct 2026 11:37:31 -0400

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets.

The specialized Dutch patent court in the Hague ruled that Merck infringed Halozyme's MDASE patent EP 2,797,622 and ordered MSD BV to halt manufacturing, offering, placing on the market, using, importing or stocking Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The court also rejected Merck's arguments that the EP622 patent is invalid.

"We're very pleased the Dutch court recognized the validity and infringement of Halozyme's MDASE patent EP622 and granted an

Dutch court orders Merck to halt Keytruda SC sales in 8 countries

Wed, 07 Oct 2026 08:30:20 -0400

A specialized Dutch patent court in The Hague has ruled that Merck infringed a Halozyme Therapeutics (NASDAQ: HALO) patent and ordered Merck's European subsidiary, MSD BV, to stop manufacturing, offering, selling, importing, and stocking Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands.

The court found that Keytruda SC infringes Halozyme's MDASE patent EP 2,797,622 and rejected Merck's arguments that the patent is invalid. The injunction also prohibits MSD BV from facilitating infringement by its affiliates, including through use of its European Marketing Authorization.

Halozyme's Chief Legal Officer Mark Snyder said in a statement: "We're very pleased the

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

Wed, 07 Oct 2026 08:30:00 -0400

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

Wed, 07 Oct 2026 08:30:00 -0400

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and

H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Wed, 07 Oct 2026 06:49:36 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $115.00 price target on Halozyme Therapeutics (NASDAQ: HALO)
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $109.72 yesterday.

Halozyme expands argenx deal to cover two more drug targets

Tue, 06 Oct 2026 16:05:14 -0400

Halozyme Therapeutics (NASDAQ: HALO) has expanded its global collaboration and license agreement with argenx to include two additional exclusive targets using its ENHANZE® drug delivery technology, according to a press release from the San Diego-based company.

The expansion increases argenx's exclusive access to ENHANZE from six to eight targets. The technology is used to develop subcutaneous formulations of injectable drugs, allowing patients to receive treatments outside of clinical settings.

The two companies previously worked together to develop VYVGART Hytrulo, a subcutaneous treatment for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

Under the terms of the expanded agreement, Halozyme is eligible to receive milestone

StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)

Halozyme Therapeutics (HALO) PT Raised to $130 at TD Cowen

H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Form 4 HALOZYME THERAPEUTICS, For: Oct 06 Filed by: Torley Helen

Form 4/A HALOZYME THERAPEUTICS, For: May 05 Filed by: Connaughton Bernadette

Halozyme Therapeutics (HALO) PT Raised to $78 at JPMorgan

Halozyme stock rises after winning injunction against Merck

Halozyme stock rises after winning injunction against Merck

Halozyme stock rises after winning injunction against Merck

Halozyme stock rises after winning injunction against Merck

Dutch court orders Merck to halt Keytruda SC sales in 8 countries

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Halozyme expands argenx deal to cover two more drug targets